<DOC>
	<DOC>NCT01714089</DOC>
	<brief_summary>The purpose of this study is to determine whether RNS60 is effective in the treatment of RR-MS compared to interferon beta-1a.</brief_summary>
	<brief_title>Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>1. Males or females, aged between 18 and 50 years. 2. Diagnosis of RRMS according to McDonald 2010 diagnostic criteria with a prior brain MRI that demonstrates lesions consistent with RRMS, both within the past year. 3. No evidence of relapse during the 60 days prior to enrollment. 4. EDSS score of 05 at screening. 5. Women of childbearing potential who have a negative pregnancy test (serum HCG) at screening. 6. Men or women of reproductive potential who commit to use adequate contraception during the study and for 1 month following the last day of treatment. 7. Subjects must be capable of understanding the purpose and risks of the study and provide written, informed consent. 1. Diagnosis of Secondary Progressive MS, Primary Progressive MS or Progressive Relapsing MS. 2. Normal baseline brain MRI. 3. History of any clinically significant autoimmune disease: inflammatory bowel disease, diabetes, lupus or severe asthma. 4. Current or prior malignancies (excluding nonmelanoma skin carcinoma or in situ carcinoma of the cervix that has been adequately treated.) 5. Significant organ dysfunction, including cardiac, renal (eGFR ≤ 60 ml/min.), liver, central nervous system, pulmonary, vascular, gastrointestinal, endocrine, or metabolic (e.g., creatinine ≥ 1.6 mg/dL; ALT or AST ≥ 1.5x the upper limit of normal), history of myocardial infarction, congestive heart failure, or arrhythmias within 6 months prior to enrollment. 6. Steroid therapy within 60 days prior to enrollment, with the exception of corticosteroids or ACTH for relapse treatment during the course of the study. 7. Known allergy to GadoliniumDTPA 8. Therapy with any immunomodulatory drugs within 3 months prior to enrollment, including but not limited to interferons, glatiramir acetate, BG12, teriflunomide, laquinimod and IV immunoglobulin. 9. Treatment at any time with immunosuppressive drugs such as cladribine, total lymphoid irradiation, monoclonal antibody treatment, mitoxantrone, Tysabri, fingolimod, cytoxan, methotrexate. 10. Participation in any investigational therapy within one year prior to enrollment, unless given approval by PI. 11. Known or suspected current or past alcohol or drug abuse within one year prior to enrollment. 12. Any medical, psychiatric or other condition that could result in a subject not being able to comply with protocol requirements.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Relapsing remitting multiple sclerosis</keyword>
	<keyword>RR-MS</keyword>
</DOC>